X0306 4 2019-09-17 0 0001692830 Satsuma Pharmaceuticals, Inc. STSA 0001657768 TAKANASHI KEN C/O SATSUMA PHARMACEUTICALS, INC. 400 OYSTER POINT BOULEVARD, SUITE 221 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock, $0.0001 par value 2019-09-17 4 C 0 33741 A 1021276 I See FN Common Stock, $0.0001 par value 2019-09-17 4 C 0 307110 A 1328386 I See FN Common Stock, $0.0001 par value 2019-09-17 4 P 0 233333 15.00 A 1561719 I See FN Series A Preferred Stock 2019-09-17 4 C 0 33741 D Common Stock 33741 0 I See FN Series B Preferred Stock 2019-09-17 4 C 0 307110 D Common Stock 307110 0 I See FN Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering. Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering. Shares are held by Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"). Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities. SNBL USA, Ltd., a subsidiary of SNBL, purchased an additional 233,333 shares of issuer's common stock in connection with the initial public offering at the offering price of $15.00 per share. /s/ Thomas P. O'Neil as Attorney-in-Fact for Ken Takanashi 2019-09-17